2 results
Approved WMOPending
The objective of this phase-3 randomized study, with a double-blind treatment period of 8 weeksduration is to evaluate the efficacy and safety of the fixed dose combinations of TAK-491 pluschlorthalidone (40/12.5 mg and 40/25 mg) in subjects with…
Approved WMORecruiting
The main objective is to evaluate the average time span within which *time of onset* and *time of offset* occurs in patients with overactive bladder syndrome or non-obstructive urinary retention who respond to SNM.